Last reviewed · How we verify

NCT04775446: MESOIMMUNE

Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy

Completed Last updated 4 February 2022
What this trial tests

trial testing Data collection in Malignant Pleural Mesothelioma in 116 participants. Completed in 11 October 2021.

Timeline
26 November 2020
Primary endpoint
11 October 2021
11 October 2021

Quick facts

Lead sponsorCentre Hospitalier Intercommunal Creteil
StatusCompleted
Study typeOBSERVATIONAL
Enrollment116
Start date26 November 2020
Primary completion11 October 2021
Estimated completion11 October 2021
Sites5 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Intercommunal Creteil

Who can join

18 and older, any sex, with Malignant Pleural Mesothelioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this multicentre descriptive analysis is to describe the clinical and biological characteristics of patients who have received Programmed cell death 1 (anti-PD1) / (PDL1) Programmed death-ligand 1 (PDL1) immunotherapy outside of a clinical trial in terms of efficacy and safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for Malignant Pleural Mesothelioma

Currently open trials in the same condition.

Other Centre Hospitalier Intercommunal Creteil trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04775446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing